PLAG1 antibody
- Known as:
- PLAG1 (anti-)
- Catalog number:
- orb101852
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- Biorbyt biorb
- Gene target:
- PLAG1 antibody
Related genes to: PLAG1 antibody
- Gene:
- PLAG1 NIH gene
- Name:
- PLAG1 zinc finger
- Previous symbol:
- -
- Synonyms:
- ZNF912
- Chromosome:
- 8q12.1
- Locus Type:
- gene with protein product
- Date approved:
- 1998-02-11
- Date modifiied:
- 2016-11-01
Related products to: PLAG1 antibody
Related articles to: PLAG1 antibody
- PLAG1 immunohistochemistry and FISH were essential for diagnosis of extra-uterine myxoid leiomyosarcoma and should be considered in myxoid intra-abdominal tumors, especially in patients with previous uterine surgery. - Source: PubMed
Publication date: 2026/09/16
Hsieh Cheng-EnWu Po-HsuanSu Chang-WeiMa Yu-ChunHuang Hsuan-Ying - Salivary gland neoplasms (SGNs) represent a diverse group of benign and malignant tumors characterized by distinct genetic abnormalities that contribute to their pathogenesis and variable clinical behavior. This review synthesizes current evidence on the molecular alterations underlying SGNs and highlights emerging therapeutic targets with translational potential. A comprehensive literature search was conducted across PubMed, Google Scholar, Cochrane, and SCOPUS for studies published between 1990 and 2025, focusing on genetic aberrations, oncogenic fusions, and targeted treatment strategies. Data reveal that small molecule inhibitors and other targeted agents may offer promising alternatives to conventional chemotherapy. For instance, pleomorphic adenomas often have PLAG1 overexpression and FGFR1 fusions, activating the IGF and WNT signaling pathways; linsitinib, a dual IGF1R and tyrosine kinase inhibitor, has demonstrated antitumor activity in other malignancies and may hold potential in this context. Similarly, alterations in EGFR, HER2, and PI3K pathways across multiple salivary tumor subtypes highlight opportunities for small molecular inhibitor therapy. However, current data remain limited, and therapeutic applications are largely extrapolated from other cancers. Further research is needed to validate these findings in clinical trials. Overall, integrating molecular diagnostics with pathway-specific targeted therapies may enhance outcomes and expand treatment options for patients with SGNs. - Source: PubMed
Publication date: 2026/09/15
Kota SharwaniSmith Richard V - Pleomorphic adenoma is a common benign minor salivary gland tumor of the oral cavity, with the palate being the most common site. Considering the local anatomy, profuse vascularity, and proximity to vital structures, diagnosis and surgical management present specific challenges. The lack of a true capsule in minor gland lesions, the associated risk of recurrence, and potential for malignant transformation are key factors to consider when formulating a treatment plan. This case report highlights early diagnosis and management, and reviews the literature on management protocols and the importance of long-term follow-up in such cases. - Source: PubMed
Publication date: 2026/09/14
Singh Anup KYadav Rekha CPandey Satyanarayan - Pleomorphic adenoma is the most common benign salivary gland tumor and most frequently arises in the parotid gland. Although benign, it can recur and may undergo malignant transformation, underscoring the need for experimental models that preserve native tissue features over time. In this study, fresh tumor tissue from six patients with primary histologically benign pleomorphic adenoma was divided into fragments of approximately 3 × 3 mm in surface dimensions and approximately 3 mm in thickness and maintained in a patient-derived three-dimensional organotypic co-culture for up to 21 days. The primary longitudinal analysis compared baseline tissue with matched fragments harvested at days 14 and 21. Histology and immunohistochemistry were assessed in three randomly selected high-power fields within morphologically viable, tumor-containing regions; necrotic or degenerative areas were excluded. Ki-67-positive cell nuclei remained within the predefined low category at all retained time points. PLAG1 positivity was retained in all cases but was more variable by day 21, while epithelial and myoepithelial-associated markers showed marker- and case-dependent patterns. CD45-positive cells remained detectable in sampled viable compartments, whereas SSTR2 was commonly reduced after baseline. These findings support the use of the 3D-OTC platform for longitudinal histomorphologic and selected biomarker assessment within surviving viable tissue compartments. Because whole-fragment necrosis and diffusion of oxygen, nutrients, or test compounds were not quantified, the present data do not establish uniform full-thickness viability or validate the platform for therapeutic-response testing. - Source: PubMed
Publication date: 2026/09/13
Hoch Cosima CWeiser TobiasStögbauer FabianJohnson FelixMulthoff GabrieleBashiri Dezfouli AliWollenberg Barbara - Nasopharyngeal carcinoma (NPC) is a multifactorial disease driven by both genetic and environmental factors. The neurogenic locus notch homolog 1 (NOTCH1) gene has dual oncogenic and tumor-suppressive effects that depend on the cellular context. An intronic single nucleotide polymorphism (SNP) in NOTCH1, rs3124599, has been linked to various diseases. However, its involvement in NPC remains unknown. This study aims to explore the regulatory and susceptibility effects of rs3124599 on NPC. - Source: PubMed
Publication date: 2026/08/31
Sultan Mujeeb ARomdhoni Achmad ChusnuWungu Citrawati Dyah KenconoPurwono Priyo Budi